https://old.international-biopharma.com/4-drugs-facing-key-patent-expirations-and-potential-generic-entry-from-september-2021-november-2021/ 2021-12-09T15:14:57+00:00 https://old.international-biopharma.com/shoring-up-diagnostics-manufacturing-for-the-next-pandemic/ 2021-12-09T15:14:27+00:00 https://old.international-biopharma.com/early-tests-suggest-vir-gsk-antibody-could-hold-up-versus-omicron/ 2021-12-03T12:55:25+00:00 https://old.international-biopharma.com/a-startup-led-by-novartis-veteran-raises-80m-to-develop-gene-therapies-for-the-brain/ 2021-12-03T12:52:31+00:00 https://old.international-biopharma.com/facing-challenges-deciphera-cuts-workforce-by-a-third/ 2021-12-03T12:48:26+00:00 https://old.international-biopharma.com/regeneron-warns-its-antibody-drug-may-be-less-potent-versus-omicron/ 2021-12-03T12:45:31+00:00 https://old.international-biopharma.com/blueprint-taking-aim-at-larger-drugmakers-becomes-a-biotech-buyer/ 2021-12-03T12:42:50+00:00 https://old.international-biopharma.com/new-merck-study-results-raise-questions-about-its-covid-pill/ 2021-12-03T12:36:49+00:00 https://old.international-biopharma.com/vaccine-makers-move-quickly-to-confront-omicron-threat/ 2021-12-03T12:32:06+00:00 https://old.international-biopharma.com/media-information-2019/ 2021-11-30T12:22:07+00:00 https://old.international-biopharma.com/takeda-wins-us-approval-for-new-cmv-treatment/ 2021-11-26T13:35:31+00:00 https://old.international-biopharma.com/biogen-seeking-more-information-in-investigation-of-aduhelm-patients-death/ 2021-11-26T13:32:35+00:00 https://old.international-biopharma.com/a-worrisome-safety-signal-slows-mercks-hiv-ambitions/ 2021-11-26T13:30:54+00:00 https://old.international-biopharma.com/fda-aiming-to-curb-another-covid-19-surge-clears-pfizer-moderna-boosters-for-all-adults/ 2021-11-26T13:28:50+00:00 https://old.international-biopharma.com/bluebird-after-delays-gets-speedy-fda-review-for-beta-thalassemia-gene-therapy/ 2021-11-26T13:26:54+00:00 https://old.international-biopharma.com/neurocrine-stocks-up-on-a-biotechs-psychiatric-drugs/ 2021-11-26T13:22:51+00:00 https://old.international-biopharma.com/pfizer-biontech-to-seek-full-approval-as-covid-19-vaccine-efficacy-holds-up-in-young-teens/ 2021-11-26T13:20:55+00:00 https://old.international-biopharma.com/biden-nominates-robert-califf-to-return-as-fda-head/ 2021-11-19T10:07:59+00:00 https://old.international-biopharma.com/anticipating-aduhelms-costs-medicare-plans-big-jump-in-premiums/ 2021-11-19T10:03:55+00:00 https://old.international-biopharma.com/pfizer-will-allow-generic-drugmakers-to-produce-promising-covid-19-pill/ 2021-11-19T09:58:20+00:00 https://old.international-biopharma.com/as-congress-weighs-drug-price-restraints-icer-calls-out-unsupported-increases/ 2021-11-19T09:55:56+00:00 https://old.international-biopharma.com/pfizer-asks-fda-to-authorize-covid-19-pill/ 2021-11-19T09:52:34+00:00 https://old.international-biopharma.com/fda-approves-mercks-keytruda-as-first-immunotherapy-for-early-kidney-cancer/ 2021-11-19T09:50:29+00:00 https://old.international-biopharma.com/roche-cuts-ties-with-atea-after-covid-19-pills-trial-failure/ 2021-11-19T09:49:04+00:00 https://old.international-biopharma.com/beam-gets-green-light-to-begin-first-clinical-test-of-base-editing/ 2021-11-15T09:23:05+00:00 https://old.international-biopharma.com/mirati-gives-first-look-at-kras-drug-combination-in-lung-cancer/ 2021-11-15T09:22:25+00:00 https://old.international-biopharma.com/us-pays-1b-to-nearly-double-supply-of-mercks-covid-19-pill/ 2021-11-15T09:21:33+00:00 https://old.international-biopharma.com/pfizer-again-asks-fda-to-authorize-covid-19-boosters-for-all-adults/ 2021-11-15T09:20:49+00:00 https://old.international-biopharma.com/pfizer-buys-into-biohavens-fast-selling-migraine-medicine/ 2021-11-15T09:20:12+00:00 https://old.international-biopharma.com/fibrogen-cuts-jobs-as-it-weighs-anemia-drugs-future-in-us/ 2021-11-15T09:19:16+00:00 https://old.international-biopharma.com/cortexyme-plans-path-forward-for-alzheimers-drug-that-failed-study/ 2021-11-15T09:18:42+00:00 https://old.international-biopharma.com/insurers-sue-merck-for-monopolistic-scheme-to-delay-generics-of-blockbuster-cholesterol-drug/ 2021-11-10T16:57:22+00:00 https://old.international-biopharma.com/as-fda-scrutinizes-immunotherapy-approvals-merck-says-keytruda-extends-survival-in-liver-cancer-trial/ 2021-11-10T16:56:31+00:00 https://old.international-biopharma.com/biohavens-pipeline-takes-a-hit-as-drug-for-rare-neurological-disease-falls-short-in-trial/ 2021-11-10T16:55:09+00:00 https://old.international-biopharma.com/fda-lifts-hold-on-genetx-ultragenyx-study-of-angelman-therapy/ 2021-11-10T16:33:49+00:00 https://old.international-biopharma.com/astrazeneca-strikes-deal-with-university-spinoff-to-turn-rna-into-drugs/ 2021-11-10T16:33:06+00:00 https://old.international-biopharma.com/sanofi-claims-positive-early-data-for-mrna-covid-shot-but-pivots-to-flu-instead/ 2021-11-10T16:32:24+00:00 https://old.international-biopharma.com/top-fda-official-takes-over-vaccine-office-as-agency-weighs-covid-19-shots-for-kids/ 2021-11-10T16:31:21+00:00 https://old.international-biopharma.com/back-to-in-person-events-sonotec-presents-high-accuracy-flow-meters-for-enhanced-process-quality-and-reproducibility-on-bioprocessing-fall-shows-in-the-usa/ 2021-11-10T16:30:39+00:00 https://old.international-biopharma.com/curevac-scales-back-mrna-manufacturing-for-coronavirus-vaccine/ 2021-11-10T16:29:39+00:00 https://old.international-biopharma.com/biotech-funder-lightstone-raises-another-375m-for-life-sciences-investing/ 2021-11-10T16:29:14+00:00 https://old.international-biopharma.com/us-stocks-up-on-covid-19-antibody-drugs-amid-shortage-concerns/ 2021-11-10T16:28:35+00:00 https://old.international-biopharma.com/theravance-to-lay-off-75-of-employees-alongside-larger-restructuring/ 2021-11-10T16:27:52+00:00 https://old.international-biopharma.com/takeda-wins-fda-approval-for-targeted-lung-cancer-drug/ 2021-11-10T16:27:03+00:00 https://old.international-biopharma.com/fda-halts-tests-of-biomarin-drug-amid-heightened-focus-on-gene-therapy-safety/ 2021-11-10T16:25:42+00:00 https://old.international-biopharma.com/sanofi-to-buy-kadmon-for-1-9b-extending-deal-streak/ 2021-11-10T16:25:00+00:00 https://old.international-biopharma.com/lilly-joins-rna-editing-race-with-proqr-deal/ 2021-11-10T16:24:16+00:00 https://old.international-biopharma.com/roche-bets-big-on-off-the-shelf-cancer-cell-therapy-with-adaptimmune-deal/ 2021-11-10T16:23:31+00:00 https://old.international-biopharma.com/autism-drug-fails-in-late-stage-trials-servier-says/ 2021-11-10T16:22:35+00:00 https://old.international-biopharma.com/optibrium-releases-3d-ligand-based-design-module-for-stardrop-drug-discovery-software/ 2021-11-10T16:21:42+00:00 https://old.international-biopharma.com/moderna-founders-next-big-play-in-rna-raises-440m/ 2021-11-10T16:20:40+00:00 https://old.international-biopharma.com/galapagos-ceo-to-retire-though-successor-yet-to-be-announced/ 2021-11-10T16:18:59+00:00 https://old.international-biopharma.com/after-coronavirus-success-jj-hits-setback-with-hiv-vaccine/ 2021-11-10T16:17:59+00:00 https://old.international-biopharma.com/hint-of-benefit-in-alzheimers-drug-study-fuel-stock-surge-for-swiss-biotech/ 2021-11-10T16:17:14+00:00 https://old.international-biopharma.com/novartis-finalizes-deal-to-make-new-heart-drug-widely-available-in-england/ 2021-11-10T16:15:54+00:00 https://old.international-biopharma.com/pfizer-marking-fast-research-pace-starts-key-trial-of-rsv-vaccine/ 2021-11-10T16:13:02+00:00 https://old.international-biopharma.com/avacta-appoints-dr-fiona-mclaughlin-as-chief-scientific-officer-of-its-therapeutics-division/ 2021-11-10T16:11:46+00:00 https://old.international-biopharma.com/lims-and-iso-iec-17025-an-opportunity-not-a-burden/ 2021-11-10T15:59:54+00:00 https://old.international-biopharma.com/regulatory-compliance-how-lims-can-support-the-10-principles-of-gmp/ 2021-11-10T15:56:18+00:00 https://old.international-biopharma.com/fda-grants-full-approval-to-pfizer-biontechs-coronavirus-vaccine/ 2021-11-10T14:59:32+00:00 https://old.international-biopharma.com/pfizer-stocks-cancer-drug-pipeline-with-2-3b-deal-for-trillium/ 2021-11-10T14:56:51+00:00 https://old.international-biopharma.com/with-new-results-jjs-1b-gamble-on-a-targeted-inflammation-drug-faces-long-odds/ 2021-11-10T14:55:32+00:00 https://old.international-biopharma.com/vertex-looking-to-broaden-its-gene-editing-abilities-asks-a-young-biotech-for-help/ 2021-11-10T14:54:25+00:00 https://old.international-biopharma.com/new-data-bolster-regenerons-plan-to-defend-top-selling-eye-drug/ 2021-11-10T14:53:18+00:00 https://old.international-biopharma.com/astrazeneca-reports-study-success-for-rare-disease-drug-acquired-in-alexion-deal/ 2021-11-10T14:51:46+00:00 https://old.international-biopharma.com/merck-wins-approval-for-cancer-drug-acquired-in-2019-biotech-buyout/ 2021-11-10T14:48:24+00:00 https://old.international-biopharma.com/lillys-new-eczema-drug-scores-in-late-stage-studies/ 2021-11-10T14:46:34+00:00 https://old.international-biopharma.com/fda-clears-rocket-to-resume-testing-gene-therapy-for-a-rare-heart-disease/ 2021-11-10T14:45:11+00:00 https://old.international-biopharma.com/lilly-preparing-alzheimers-drug-plans-forms-new-neuroscience-unit-in-company-restructure/ 2021-11-10T14:44:10+00:00 https://old.international-biopharma.com/private-equity-dives-deeper-into-biotech-with-nearly-2b-bain-fundraise/ 2021-11-10T14:42:55+00:00 https://old.international-biopharma.com/gsk-in-race-to-catch-up-with-rivals-wins-expanded-approval-for-cancer-drug/ 2021-11-10T14:42:00+00:00 https://old.international-biopharma.com/startup-eqrx-to-take-drug-price-mission-public-through-1-8b-spac-deal/ 2021-11-10T14:40:55+00:00 https://old.international-biopharma.com/how-bayer-lured-a-biotech-away-from-an-ipo-and-into-a-buyout/ 2021-11-10T14:39:00+00:00 https://old.international-biopharma.com/moderna-says-vaccine-protective-through-six-months-but-warns-boosters-needed-this-fall/ 2021-11-10T14:37:58+00:00 https://old.international-biopharma.com/regeneron-drug-extends-survival-in-lung-cancer-trial-lifting-companys-hopes-in-field/ 2021-11-10T14:36:34+00:00 https://old.international-biopharma.com/gileads-kite-bets-on-early-stage-biotech-to-advance-allogeneic-cell-therapies/ 2021-11-10T14:32:48+00:00 https://old.international-biopharma.com/hhs-watchdog-to-review-fda-accelerated-approval-process-after-aduhelm-controversy/ 2021-11-10T14:28:35+00:00 https://old.international-biopharma.com/in-a-first-fda-approves-an-interchangeable-biosimilar-for-diabetes/ 2021-11-10T14:19:52+00:00 https://old.international-biopharma.com/fda-rejects-a-biotechs-kidney-drug-but-some-analysts-still-see-a-sliver-of-hope/ 2021-11-10T14:18:40+00:00 https://old.international-biopharma.com/pfizers-fast-progress-shines-spotlight-on-an-emerging-vaccine-race/ 2021-11-10T14:17:16+00:00 https://old.international-biopharma.com/astrazeneca-wins-first-fda-approval-for-systemic-lupus-drug-in-a-decade/ 2021-11-10T14:16:07+00:00 https://old.international-biopharma.com/sarepta-adds-another-gene-therapy-to-its-ever-expanding-pipeline/ 2021-11-10T14:13:43+00:00 https://old.international-biopharma.com/amgen-expecting-higher-demand-for-its-medicines-to-build-plant-in-north-carolina/ 2021-11-10T14:11:35+00:00 https://old.international-biopharma.com/bio-rad-launches-iga-and-igm-sars-cov-2-bio-plex-pro-immunoassay-panels-to-study-covid-19-antibody-response/ 2021-11-10T13:59:20+00:00 https://old.international-biopharma.com/jj-asks-fda-to-clear-booster-dose-of-its-coronavirus-vaccine/ 2021-11-10T13:57:58+00:00 https://old.international-biopharma.com/under-pressure-to-share-technology-moderna-to-build-vaccine-factory-in-africa/ 2021-11-10T13:56:34+00:00 https://old.international-biopharma.com/sarepta-embarks-on-late-stage-clinical-trial-of-duchenne-gene-therapy/ 2021-11-10T13:55:32+00:00 https://old.international-biopharma.com/collins-to-step-down-as-nih-head-in-transition-for-research-agency/ 2021-11-10T13:53:47+00:00 https://old.international-biopharma.com/gene-therapy-developer-gets-chance-at-a-comeback-with-pfizer-deal/ 2021-11-10T13:44:33+00:00 https://old.international-biopharma.com/bristol-myers-top-autoimmune-drug-prospect-takes-a-hit-in-mid-stage-trial/ 2021-11-10T13:42:53+00:00 https://old.international-biopharma.com/how-a-busy-year-for-biotech-ipos-measures-up-at-the-three-quarter-mark/ 2021-11-10T13:41:25+00:00 https://old.international-biopharma.com/b-medical-systems-production-area-extension/ 2021-11-10T13:39:03+00:00 https://old.international-biopharma.com/wp-content/uploads/2021/10/Luxembourg-factory-launch-scaled.jpg https://old.international-biopharma.com/wp-content/uploads/2021/10/Luc-CEO-scaled.jpg https://old.international-biopharma.com/wp-content/uploads/2021/10/IMG_5528.heic https://old.international-biopharma.com/wp-content/uploads/2021/10/Picture-1.jpg https://old.international-biopharma.com/merck-ridgeback-seek-us-clearance-of-first-oral-covid-19-drug/ 2021-11-10T13:37:51+00:00 https://old.international-biopharma.com/adamas-flexion-sell-for-825m-combined-as-biotechs-dealmaking-pace-picks-up/ 2021-11-10T13:36:01+00:00 https://old.international-biopharma.com/merck-advantage-grows-as-fda-approves-keytruda-for-first-line-cervical-cancer/ 2021-11-10T13:34:41+00:00 https://old.international-biopharma.com/lilly-drug-cleared-by-fda-for-wider-use-in-breast-cancer/ 2021-11-10T13:33:38+00:00 https://old.international-biopharma.com/curevac-scraps-its-first-covid-19-vaccine-and-pivots-to-a-second/ 2021-11-10T13:32:34+00:00 https://old.international-biopharma.com/astrazeneca-builds-case-for-long-acting-covid-19-drug-but-is-it-too-late/ 2021-11-10T13:30:50+00:00 https://old.international-biopharma.com/sonotec-with-new-sensor-generation-at-interphex-ny/ 2021-11-10T13:29:41+00:00 https://old.international-biopharma.com/gates-foundation-pledges-120m-to-bring-merck-covid-19-drug-to-lower-income-countries/ 2021-11-10T13:28:19+00:00 https://old.international-biopharma.com/cdc-panel-levels-playing-field-for-new-merck-pfizer-pneumonia-vaccines/ 2021-11-10T13:27:01+00:00 https://old.international-biopharma.com/jj-foresees-end-to-not-for-profit-sales-of-coronavirus-vaccine/ 2021-11-10T13:16:08+00:00 https://old.international-biopharma.com/atea-roche-change-plans-for-oral-covid-19-drug-after-trial-setback/ 2021-11-10T13:14:48+00:00 https://old.international-biopharma.com/boehringer-ingelheim-takes-next-step-in-development-of-cystic-fibrosis-gene-therapy/ 2021-11-10T13:08:36+00:00 https://old.international-biopharma.com/biogens-closely-watched-als-drug-comes-up-short-in-late-stage-study/ 2021-11-10T13:07:33+00:00 https://old.international-biopharma.com/sgs-increases-biosafety-testing-capacity-at-its-glasgow-facility/ 2021-11-10T13:06:31+00:00 https://old.international-biopharma.com/wp-content/uploads/2021/10/SGS-Glasgow-Facility-Expansion.png https://old.international-biopharma.com/merck-agrees-to-license-covid-19-pill-widely-through-pact-with-patent-group/ 2021-11-10T13:03:39+00:00 https://old.international-biopharma.com/with-approval-plans-underway-lillys-next-move-is-to-test-its-alzheimers-drug-against-biogens/ 2021-11-10T11:56:23+00:00 https://old.international-biopharma.com/fda-advisers-support-pfizers-coronavirus-vaccine-for-young-children/ 2021-11-10T11:29:17+00:00 https://old.international-biopharma.com/takeda-reels-in-a-cell-therapy-research-partner-with-build-to-buy-deal/ 2021-11-10T10:45:24+00:00 https://old.international-biopharma.com/novartis-to-consider-sale-or-separation-of-sandoz-business/ 2021-11-10T10:36:11+00:00 https://old.international-biopharma.com/vertex-aligns-with-another-crispr-gene-editing-startup/ 2021-11-10T10:34:55+00:00 https://old.international-biopharma.com/novartis-hits-another-setback-in-plan-to-repurpose-rare-disease-drug-in-lung-cancer/ 2021-11-10T10:33:13+00:00 https://old.international-biopharma.com/sphere-fluidics-closes-a-40-million-funding-round-led-by-sofinnova-partners-and-redmile-group/ 2021-11-10T10:32:09+00:00 https://old.international-biopharma.com/fda-extends-review-of-jj-legends-cell-therapy-for-multiple-myeloma/ 2021-11-08T14:12:18+00:00 https://old.international-biopharma.com/amylyx-asks-fda-to-approve-als-drug-while-also-preparing-late-stage-study/ 2021-11-08T14:09:01+00:00 https://old.international-biopharma.com/moderna-teaming-with-a-startup-wades-further-into-gene-editing/ 2021-11-08T14:06:27+00:00 https://old.international-biopharma.com/pfizer-gene-therapy-research-delayed-by-trial-changes-safety-questions/ 2021-11-08T14:04:40+00:00 https://old.international-biopharma.com/cdc-panel-unanimously-backs-use-of-pfizers-covid-19-vaccine-in-young-children/ 2021-11-08T14:01:49+00:00 https://old.international-biopharma.com/merck-wins-uk-authorization-to-sell-first-covid-19-pill/ 2021-11-08T13:58:56+00:00 https://old.international-biopharma.com/caribou-raises-304m-in-one-of-gene-editings-most-lucrative-ipos/ 2021-07-29T14:48:22+00:00 https://old.international-biopharma.com/biontech-who-hatch-plan-to-bring-mrna-vaccines-to-africa/ 2021-07-29T14:47:17+00:00 https://old.international-biopharma.com/denali-drug-for-rare-brain-disease-disappoints-investors/ 2021-07-29T14:45:47+00:00 https://old.international-biopharma.com/bristol-myers-withdraws-opdivo-in-liver-cancer-as-fallout-from-fda-meeting-continues/ 2021-07-29T14:44:25+00:00 https://old.international-biopharma.com/regeneron-astrazeneca-team-up-on-targeted-drugs-for-obesity/ 2021-07-29T14:42:52+00:00 https://old.international-biopharma.com/merck-rebounds-to-win-a-milestone-immunotherapy-approval-in-early-breast-cancer/ 2021-07-29T14:41:34+00:00 https://old.international-biopharma.com/astrazeneca-deal-for-alexion-to-close-soon-as-uk-regulator-clears-acquisition/ 2021-07-19T09:36:08+00:00 https://old.international-biopharma.com/major-health-centers-insurers-push-back-against-aduhelm/ 2021-07-19T09:34:28+00:00 https://old.international-biopharma.com/galapagos-shares-sink-as-first-data-from-touted-drug-program-disappoints/ 2021-07-19T09:32:36+00:00 https://old.international-biopharma.com/a-cancer-drug-startup-banks-new-funds-for-nk-cell-therapy/ 2021-07-19T09:30:56+00:00 https://old.international-biopharma.com/prime-medicine-raises-315m-to-fuel-search-and-replace-gene-editing-work/ 2021-07-19T09:29:52+00:00 https://old.international-biopharma.com/lilly-wagers-up-to-1b-on-a-biotechs-plan-for-a-new-type-of-insulin/ 2021-07-19T09:28:09+00:00 https://old.international-biopharma.com/5-fda-decisions-to-watch-in-the-third-quarter/ 2021-07-09T08:48:16+00:00 https://old.international-biopharma.com/a-well-funded-cancer-drug-startup-brings-on-gsks-axel-hoos-as-ceo/ 2021-07-09T08:42:51+00:00 https://old.international-biopharma.com/lilly-boehringer-say-diabetes-drug-first-to-succeed-in-hard-to-treat-heart-failure/ 2021-07-09T08:40:42+00:00 https://old.international-biopharma.com/8-key-clinical-trials-to-watch-for-the-rest-of-2021/ 2021-07-09T08:39:18+00:00 https://old.international-biopharma.com/fda-revises-labeling-of-biogens-alzheimers-drug-to-emphasize-early-treatment/ 2021-07-09T08:30:26+00:00 https://old.international-biopharma.com/gene-therapy-for-sickle-cell-disease-progress-and-competition/ 2021-07-09T08:28:41+00:00 https://old.international-biopharma.com/a-world-leader-in-naturally-derived-products-discusses-commercial-success-and-new-innovations/ 2021-07-08T15:14:01+00:00 https://old.international-biopharma.com/supporting-mergers-and-acquisitions-in-the-pharmaceutical-biopharmaceutical-industry/ 2021-07-08T15:10:57+00:00 https://old.international-biopharma.com/dealing-with-the-challenges-of-post-translational-modifications-ptms/ 2021-07-08T15:06:55+00:00 https://old.international-biopharma.com/solving-critical-data-challenges-for-chemicallymodified-biologically-based-therapeutic-candidates/ 2021-07-08T15:03:52+00:00 https://old.international-biopharma.com/using-lentiviral-vectors-to-advance-the-development-of-therapeutic-vaccines/ 2021-07-08T14:59:58+00:00 https://old.international-biopharma.com/antibody-drug-conjugates-a-trojan-horse-story/ 2021-07-08T14:56:26+00:00 https://old.international-biopharma.com/adapting-your-preclinical-animal-model-strategies-for-a-new-world/ 2021-07-08T14:51:51+00:00 https://old.international-biopharma.com/standard-vs-hybrid-fih-trials-advantages-and-challenges/ 2021-07-08T14:47:02+00:00 https://old.international-biopharma.com/intricacies-and-future-considerations-for-the-cell-and-gene-therapy-cold-chain/ 2021-07-08T14:42:34+00:00 https://old.international-biopharma.com/four-factors-for-a-biopharmaceutical-manufacturer-to-consider-when-developing-and-managing-a-single-use-supply-chain/ 2021-07-08T14:29:49+00:00 https://old.international-biopharma.com/h96-combining-freeze-drying-and-high-pressure-homogenisation-for-ultra-fine-nanocrystal-production/ 2021-07-08T14:25:46+00:00 https://old.international-biopharma.com/data-rich-processing-the-growing-necessity-of-rd-to-gmp-manufacture/ 2021-07-08T14:21:45+00:00 https://old.international-biopharma.com/land-use-change-and-the-global-pandemic/ 2021-07-08T14:17:17+00:00 https://old.international-biopharma.com/renaissance-sri-lanka-launches-the-kumbuk-online-networking-platform/ 2021-07-02T15:34:56+00:00 https://old.international-biopharma.com/reversing-course-lilly-to-seek-fast-approval-for-experimental-alzheimers-drug/ 2021-06-25T12:51:34+00:00 https://old.international-biopharma.com/a-year-after-getting-uniqures-gene-therapy-hemophilia-patients-are-still-doing-better/ 2021-06-25T12:48:23+00:00 https://old.international-biopharma.com/third-rock-backed-startup-launches-to-develop-cell-therapies-for-ms-diabetes/ 2021-06-25T12:46:33+00:00 https://old.international-biopharma.com/incorporating-automation-and-digitalization-into-the-industrial-microbiology-workflow/ 2021-06-25T12:45:40+00:00 https://old.international-biopharma.com/arcus-claims-positive-study-results-for-lung-cancer-drug-but-shares-no-details/ 2021-06-25T12:44:53+00:00 https://old.international-biopharma.com/blackstone-to-invest-250m-in-cell-therapy-startup-backed-by-intellia-cellex/ 2021-06-25T12:43:54+00:00 https://old.international-biopharma.com/curevac-vaccine-disappoints-in-key-study-amid-unprecedented-spread-of-variants/ 2021-06-18T13:02:45+00:00 https://old.international-biopharma.com/trial-failure-dashes-biogen-hopes-for-next-alzheimers-drug/ 2021-06-18T13:01:39+00:00 https://old.international-biopharma.com/gene-editing-biotech-verve-to-raise-267m-in-large-ipo/ 2021-06-18T13:00:31+00:00 https://old.international-biopharma.com/lyophilized-products-are-on-the-rise-heres-what-you-need-to-know/ 2021-06-18T12:59:31+00:00 https://old.international-biopharma.com/regeneron-antibody-cuts-risk-of-covid-19-death-in-uk-study/ 2021-06-18T12:58:44+00:00 https://old.international-biopharma.com/former-fda-chief-hahn-joins-venture-firm-that-launched-moderna/ 2021-06-18T12:57:33+00:00 https://old.international-biopharma.com/enabling-biomarker-discovery-with-unique-functional-proteomics/ 2021-06-10T08:59:10+00:00 https://old.international-biopharma.com/biogen-alzheimers-approval-could-open-the-door-for-similar-drugs/ 2021-06-10T08:57:13+00:00 https://old.international-biopharma.com/us-bets-1-2b-on-mercks-last-hope-for-a-covid-19-drug/ 2021-06-10T08:55:15+00:00 https://old.international-biopharma.com/novo-keeps-price-in-line-with-fda-approval-of-second-obesity-shot/ 2021-06-10T08:51:34+00:00 https://old.international-biopharma.com/beigene-expands-into-cancer-cell-therapy-with-shoreline-pact/ 2021-06-10T08:50:36+00:00 https://old.international-biopharma.com/bluebird-cleared-by-fda-to-resume-studies-of-sickle-cell-gene-therapy/ 2021-06-10T08:49:37+00:00 https://old.international-biopharma.com/novartis-prostate-cancer-drug-extends-survival-in-key-test-of-radiopharmaceutical-therapy/ 2021-06-04T09:08:51+00:00 https://old.international-biopharma.com/biotech-venture-capital-still-booming-as-venbio-raises-another-550m/ 2021-06-04T09:07:13+00:00 https://old.international-biopharma.com/morphosys-to-buy-constellation-in-1-7b-deal-aided-by-unusual-funding/ 2021-06-04T09:05:39+00:00 https://old.international-biopharma.com/former-fda-official-abernethy-joins-google-health-spinoff/ 2021-06-04T09:04:38+00:00 https://old.international-biopharma.com/alkermes-prepares-for-uncertain-launch-as-fda-finally-clears-schizophrenia-drug/ 2021-06-04T09:03:46+00:00 https://old.international-biopharma.com/orchard-abandons-promising-gene-therapy-for-rare-immune-disorder/ 2021-06-04T09:02:37+00:00 https://old.international-biopharma.com/vir-gsk-win-us-nod-for-another-covid-19-antibody-drug-as-rival-falters/ 2021-05-28T10:20:15+00:00 https://old.international-biopharma.com/fda-restricts-use-of-intercept-drug-due-to-liver-injury-risk/ 2021-05-28T10:19:11+00:00 https://old.international-biopharma.com/uk-drug-contractor-to-be-sold-to-private-equity-firm-in-1-4b-deal/ 2021-05-28T10:18:06+00:00 https://old.international-biopharma.com/icer-vocal-critic-of-drug-company-pricing-turns-scrutiny-to-insurers/ 2021-05-28T10:17:03+00:00 https://old.international-biopharma.com/moderna-with-new-results-set-to-seek-vaccine-clearance-for-young-teens/ 2021-05-28T10:15:21+00:00 https://old.international-biopharma.com/a-biotech-backs-off-nash-after-trial-failure/ 2021-05-28T10:14:10+00:00 https://old.international-biopharma.com/off-the-shelf-car-t-a-tagrisso-rival-and-the-next-breast-cancer-drugs-a-look-ahead-at-asco/ 2021-05-21T12:35:50+00:00 https://old.international-biopharma.com/fda-seeking-more-consistency-from-cell-gene-therapy-developers-top-official-says/ 2021-05-21T12:34:45+00:00 https://old.international-biopharma.com/bristol-myers-details-data-for-closely-watched-cancer-immunotherapy/ 2021-05-21T12:33:53+00:00 https://old.international-biopharma.com/in-the-midst-of-a-strategic-shift-voyager-loses-ceo-and-rd-head/ 2021-05-21T12:32:48+00:00 https://old.international-biopharma.com/humira-patents-take-center-stage-as-house-panel-targets-abbvie-pricing/ 2021-05-21T12:31:54+00:00 https://old.international-biopharma.com/gammadelta-therapeutics-receives-fda-clearance-of-ind-application-for-gdx012-a-novel-allogeneic-variable-delta-1gamma-delta-t-cell-cancer-therapy/ 2021-05-21T12:22:38+00:00 https://old.international-biopharma.com/third-rock-launches-biotech-targeting-notoriously-difficult-dna-regulators/ 2021-05-14T09:08:13+00:00 https://old.international-biopharma.com/biogen-licenses-a-stroke-drug-from-japanese-drugmaker-tms/ 2021-05-14T09:07:00+00:00 https://old.international-biopharma.com/biogen-looks-to-build-better-gene-therapies-through-latest-deal/ 2021-05-14T09:05:43+00:00 https://old.international-biopharma.com/fda-authorizes-pfizers-coronavirus-vaccine-for-younger-teens/ 2021-05-14T09:04:36+00:00 https://old.international-biopharma.com/merck-with-new-breast-cancer-data-aims-to-rebound-from-fda-rejection/ 2021-05-14T09:03:26+00:00 https://old.international-biopharma.com/amgen-asks-fda-for-approval-of-key-asthma-drug/ 2021-05-14T09:01:41+00:00 https://old.international-biopharma.com/icer-unconvinced-by-biogen-data-suggests-low-price-for-alzheimers-drug/ 2021-05-06T10:31:26+00:00 https://old.international-biopharma.com/roger-perlmutter-former-merck-research-chief-resurfaces-to-lead-a-small-biotech/ 2021-05-06T10:27:52+00:00 https://old.international-biopharma.com/pfizer-forecasts-26b-in-coronavirus-vaccine-revenue-this-year/ 2021-05-06T10:24:48+00:00 https://old.international-biopharma.com/a-worrisome-side-effect-stalls-a-closely-watched-multiple-myeloma-drug/ 2021-05-06T10:23:32+00:00 https://old.international-biopharma.com/sage-braces-for-make-or-break-depression-data/ 2021-05-06T10:22:23+00:00 https://old.international-biopharma.com/esker-a-new-biotech-startup-launches-with-plans-to-make-targeted-immune-drugs/ 2021-05-06T10:21:01+00:00